The SIGMA Group Chooses ExaGrid to Back Up Customer Data
25.6.2020 16:10:00 EEST | Business Wire | Press release
ExaGrid ® today announced that INFIDIS, a global IT integrator and solutions provider, led The SIGMA Group to choose ExaGrid’s tiered backup storage solution to enhance data protection and optimize its backups and data restoration capabilities, needed to offer its customers backup as a service.
The SIGMA Group is a digital services company based in France, specialized in software publishing, integration of tailor-made digital solutions, and outsourcing of information systems and cloud solutions. The SIGMA Group now uses ExaGrid to store customer backups, as well as its own backed up data, in addition to using ExaGrid to replicate data from its primary site to its disaster recovery (DR) site. Adding ExaGrid to The SIGMA Group’s backup environment has allowed the company to keep up with customer data growth and deliver on its SLAs.
“To meet Sigma's expectations, INFIDIS proposed the ExaGrid solution because of the many benefits it offers such as performance that is guaranteed over time, predictable costs, a scalable architecture which allows for progressive and granular investments as needed, very fast tape copy, and easily maintained long-term retention,” said Frédéric Floret, IT Business Engineer at INFIDIS.
“Using ExaGrid allows us to provide high-quality backup services to our customers,” said Mickaël Collet, cloud architect at The SIGMA Group. “We guarantee high SLAs especially on backup services and ExaGrid helps us to deliver on those. Our backup services include performance commitments on restorations and ExaGrid’s Landing Zone allows us to keep the freshest data in a non-deduplicated format to guarantee optimal restoration performance.”
The SIGMA Group is responsible for backing up 650TB of customer data, which is backed up in daily incrementals, as well as weekly and monthly fulls. The SIGMA Group’s IT staff have found that ExaGrid’s unique scale-out architecture has been helpful in keeping up with growing data. “We need to adjust capacity as closely as possible to customer needs and not have to oversize backup infrastructures based on growth forecasts,” said Alexandre Chaillou, infrastructure manager at The SIGMA Group. “We started with two ExaGrid systems, with one appliance at our primary data center and one at our remote data center. We expanded our two ExaGrid systems, which now are made up of 14 ExaGrid appliances. ExaGrid’s scale-out approach allows us to add capacity while making it possible to only add what is needed.”
ExaGrid writes backups directly to a disk-cache Landing Zone, avoiding inline processing and ensuring the highest possible backup performance, which results in the shortest backup window. Adaptive Deduplication performs deduplication and replication in parallel with backups while providing full system resources to the backups for the shortest backup window.
All of ExaGrid’s appliances contain not just disk but also processing power, memory, and bandwidth. When the system needs to expand, additional appliances are simply attached to the existing system. This type of configuration allows the system to maintain all the aspects of performance as the amount of data grows, allowing organizations to pay for what they need when they need it. Appliances of any size or age can be mixed and matched in a single system with capacities of up to a 2PB full backup plus retention and an ingest rate of up to 432TB per hour. Once virtualized, they appear as a single system to the backup server, and load balancing of all data across servers is automatic.
Read the complete Success Story to learn more about The SIGMA Group’s experience using ExaGrid. ExaGrid’s published customer success stories and enterprise stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivaled customer support.
About INFIDIS
INFIDIS is a 20-year-old global IT integrator and solutions provider that is in line with industry leaders. Its solution architects and engineers design, build, deliver and manage IT solutions and services for customers of all sizes and from a wide variety of industries.
INFIDIS help customers to adapt their infrastructures to the requirements of their businesses by offering them high-performance and secure solutions for the optimization of data centers in heterogeneous environments. INFIDIS offers an end-to-end support, independent of constructors and editors and based on a large ecosystem of skills, supplying all the necessary bricks to the building of the base of the new generation of infrastructures.
About ExaGrid
ExaGrid provides tiered backup storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories.
ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005508/en/
Contact information
Media:
Stacey Foster
ExaGrid
sfoster@exagrid.com
508-898-2872 x248
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 10:10:00 EEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 10:00:00 EEST | Press release
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 years, she has led global teams to achieve a 100% success rate from Phase 3 development through to FDA approval for multiple programs spanning oncology, immunology and respiratory medicine. In addition, she raised funds of around $400M as founder and CEO. Across her career she has contributed to 20 drug approvals, engaging
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 10:00:00 EEST | Press release
Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network upgrades. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260803353435/en/ Adtran’s SDX 6400 Series is helping TOHKnet demonstrate how Japan’s operators can migrate to 50G PON without disrupting existing PON services. “As demand for digital services continues to grow, this trial is a key milestone for the future of fiber access in Jap
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 10:00:00 EEST | Press release
The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the project continues to captivate audiences through its
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 10:00:00 EEST | Press release
Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib, is a first-in-class oral dual-node PI3K/AKT/mTOR (PAM) pathway inhibitor, which selectively inhibits S6K and AKT1/3. Rupitasertib was purposefully and rationally designed to target S6K for potent PAM inhibition and AKT1/3 to block the AKT compensatory feedback loop, while sparing AKT2 to avoid hyperglycemia, which we believe will lead to a superior efficacy and safety profile compared to other PAM pathway inhibitors. Under the terms of the agreement, Roche will s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
